文献速递甲状腺疾病

美国老年退伍军人中甲状腺激素治疗与干扰药物的合并使用

Concurrent Use of Thyroid Hormone Therapy and Interfering Medications in Older US Veterans.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项回顾性队列研究纳入538 137例≥65岁接受甲状腺激素治疗的退伍军人,31.4%在研究期间至少合并使用一种干扰甲状腺激素代谢的药物。黑种人、西班牙裔、女性及合并症评分≥2者合并使用可能性更高,高龄(≥85岁)者更低。

要点

  • 31.4%的老年甲状腺激素使用者至少合并一种干扰甲状腺激素代谢的药物。
  • 合并症评分≥2者合并使用干扰药物的OR为2.50(95%CI 2.45-2.54)。
  • ≥85岁者合并使用干扰药物的OR为0.48(95%CI 0.47-0.48),低于65-74岁者。

核心结论

  • 近三分之一的老年甲状腺激素使用者同时使用已知干扰甲状腺激素代谢的药物,尤其在女性和少数族裔中。

研究设计与样本

  • 回顾性队列研究,2004年至2017年,中位随访56个月,数据来自退伍军人健康管理局企业数据仓库。
  • 共纳入538 137例≥65岁、在研究期间接受甲状腺激素治疗的成人。

主要发现

  • 总体168 878例(31.4%)患者在甲状腺激素治疗期间至少使用一种干扰药物。
  • 多变量分析中,黑种人/非裔美国人较白种人OR 1.25(95%CI 1.21-1.28),西班牙裔较非西班牙裔OR 1.12(95%CI 1.09-1.15)。
  • 女性较男性OR 1.11(95%CI 1.08-1.15),Charlson/Deyo合并症评分≥2较0分OR 2.50(95%CI 2.45-2.54)。
  • ≥85岁较65-74岁OR 0.48(95%CI 0.47-0.48)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Thyroid hormone management in older adults is complicated by comorbidities and polypharmacy. OBJECTIVE: Determine the prevalence of concurrent use of thyroid hormone and medications that can interfere with thyroid hormone metabolism (amiodarone, prednisone, prednisolone, carbamazepine, phenytoin, phenobarbital, tamoxifen), and patient characteristics associated with this practice. DESIGN: Retrospective cohort study between 2004 and 2017 (median follow-up, 56 months). SETTING: Veterans Health Administration Corporate Data Warehouse. PARTICIPANTS: A total of 538 137 adults ≥ 65 years prescribed thyroid hormone therapy during the study period. MAIN OUTCOME MEASURE: Concurrent use of thyroid hormone and medications interfering with thyroid hormone metabolism. RESULTS: Overall, 168 878 (31.4%) patients were on at least 1 interfering medication while on thyroid hormone during the study period. In multivariable analyses, Black/African-American race (odds ratio [OR], 1.25; 95% CI, 1.21-1.28, compared with White), Hispanic ethnicity (OR, 1.12; 95% CI, 1.09-1.15, compared with non-Hispanic), female (OR, 1.11; 95% CI, 1.08-1.15, compared with male), and presence of comorbidities (eg, Charlson/Deyo Comorbidity Score ≥ 2; OR, 2.50; 95% CI, 2.45-2.54, compared with 0) were more likely to be associated with concurrent use of thyroid hormone and interfering medications. Older age (eg, ≥ 85 years; OR, 0.48; 95% CI, 0.47-0.48, compared with age 65-74 years) was less likely to be associated with this practice. CONCLUSIONS AND RELEVANCE: Almost one-third of older adults on thyroid hormone were on medications known to interfere with thyroid hormone metabolism. Our findings highlight the complexity of thyroid hormone management in older adults, especially in women and minorities.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Livecchi R, Coe AB, Reyes-Gastelum D, et al. Concurrent Use of Thyroid Hormone Therapy and Interfering Medications in Older US Veterans. J Clin Endocrinol Metab. 2022. PMID: 35396840. doi:10.1210/clinem/dgac216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。